Home>>PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt) (Synonyms: Pituitary Adenylate Cyclase-activating Peptide (1-38))

Catalog No.GC44532

Pituitary adenylate cyclase-activating peptide (PACAP) (1-38) is a PACAP receptor agonist with IC50 values of 4, 2, and 1 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells.

Products are for research use only. Not for human use. We do not sell to patients.

PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
500μg
$677.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pituitary adenylate cyclase-activating peptide (PACAP) (1-38) is a PACAP receptor agonist with IC50 values of 4, 2, and 1 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors in rat brain membrane (IC50 = 4.45 nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 3.6, 13, and 4.7 nM, respectively). It also stimulates cAMP accumulation in H-SY5Y, SK-N-MC, and T47D cells (EC50s = 0.37, 0.26, and 0.73 nM, respectively). In vivo, in newborn pigs, PACAP (1-38) (1 μM) induces vasodilation of pial arterioles by 43%.

Reviews

Review for PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.